Christine Fleury, MD
Pulmonary Disease · Washington, DCNPI 1649435264
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $1,166 of the $1,753 with a category attached, or 66.5%. United Therapeutics Corporation accounts for 93.5% of it on its own, with 3 other manufacturers making up the rest. 2023 is the largest year on record at $1,639, more than ten times the $25 reported in 2019.
Across 15 payments — averaging $116.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- United Therapeutics Corporation$2K
- Integra Lifesciences Corporation$64
- Actelion Pharmaceuticals US, Inc.$25
- Intuitive Surgical$25
Across 76 payments — averaging $5229.38 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$257K
- Roche Products Limited$127K
- Boehringer Ingelheim International GmbH$10K
- Janssen Research & Development, LLC$3K
What the payments were for
- Travel & lodging$1,16667%
- Food & beverage$58733%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| United Therapeutics Corporation | 11 | $1,639 |
| Integra Lifesciences Corporation | 2 | $64 |
| Actelion Pharmaceuticals US, Inc. | 1 | $25 |
| Intuitive Surgical | 1 | $25 |
How this compares
$1,753 in reported general payments places this provider in the 65th percentile of 56 pulmonary disease providers in District of Columbia.
See all pulmonary disease providers in District of Columbia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 16 | $392,426 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 46 | $67,174 |
| Spiriva HandihalerTiotropium Bromide | 12 | $12,047 |
| Breo ElliptaFluticasone/Vilanterol | 19 | $9,617 |
| Spiriva RespimatTiotropium Bromide | 11 | $9,610 |
| Incruse ElliptaUmeclidinium Bromide | 17 | $8,797 |
| SymbicortBudesonide/Formoterol Fumarate | 21 | $7,843 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 17 | $1,997 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 52 | $1,848 |
| Ventolin HfaAlbuterol Sulfate | 17 | $957 |
| Azelastine Hcl | 11 | $801 |
| Prednisone | 70 | $530 |
| Fluticasone Propionate | 30 | $499 |
| MethotrexateMethotrexate Sodium | 17 | $432 |
| Montelukast Sodium | 39 | $226 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Washington
- Andrew ShorrWashington$349K
- Eric AndersonWashington$215K
- Anne OdonnellWashington$61K
- Andrew LernerWashington$19K
- Guillermo GutierrezWashington$14K
- Khalil DiabWashington$10K
- Lorenzo LeysWashington$9K
- Rebecca KrochmalWashington$9K
- Steven LernerWashington$6K
- Karen FaganWashington$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.